Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.

beta-agonist bronchodilator drugs are known to cause hypokalemia; nevertheless, successive parenteral doses are recommended for the treatment of status asthmaticus. The metabolic and cardiopulmonary effects of sequential, subcutaneous doses of terbutaline were studied in eight stable adult asthmatic patients. Each subject received terbutaline, 0.25 mg subcutaneously, followed 30 min later either by a second subcutaneous dose of terbutaline (sequential) or normal saline (single) in a randomized, double-blind, crossover fashion. Maximum reductions in plasma potassium from baseline were significantly greater (p less than 0.05) following sequential treatment compared to single treatment (-1.1 versus -0.6 mEq/L, respectively). Improvements in forced expiratory volume in 1 s were temporally related to changes in serum potassium and were significantly greater (p less than 0.01) following sequential terbutaline treatment. Prolongation of the QTc interval occurred following both treatment regimens. The change in QTc was statistically significant only following sequential treatment, increasing from 377 +/- 21 to 441 +/- 39 ms (p less than 0.05). Sequential doses of parenterally administered terbutaline result in clinically significant reductions in plasma potassium that are temporally related to changes in pulmonary function and associated with important electrocardiographic alterations.

RCT Entities:   Population Interventions Outcomes